Targeted-oncology drug developer
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 75 | Added +171% | 1,764,914 | $140,345,961 | 0.2% |
| Paul Tudor Jones / Tudor | 61 | Added +202% | 29,594 | $2,353,315 | 0.0% |
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-03-24 | SCHEDULE 13D/A | BAKER BROS. ADVISORS LP | 20.0% | High | filing |
| 2026-03-09 | SCHEDULE 13D/A | Growth Equity Opportunities 18 VGE, LLC | 4.9% | Low | filing |
| 2026-01-16 | SCHEDULE 13D/A | Growth Equity Opportunities 18 VGE, LLC | 6.3% | Med | filing |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.